Anne (Friedrich) Döring

Lead portfolio manager for the Franklin European Fund, a small / mid-capitalization equity fund. Generated small to large capitalization investment ideas across the broader European equity universe for suite of Franklin European funds; particular focus on the healthcare, industrials and technology sectors. Analyzed company business models, strategy, competitive landscape, financials and valuation to arrive at high-conviction investment recommendations.

Sourced and appraised life science venture capital investment opportunities primarily in German-speaking regions. Conducted due diligence to assess technology, business model, financial health and strategic plan of targeted companies to expand investment portfolio. Nurtured company growth and designed exit positioning of portfolio companies to maximize value. Developed a broad network with the European investment community, including start-ups and venture capitalists.

Evaluated Merck's Research & Development programs for executive management to optimize annual R&D spend of $4B. Advised product development teams on financial aspects of managing a product from early stage discovery through patent expiry, contributing to executive committee presentations for go/no-go decisions.

Sellside equity research coverage of the US Specialty Pharmaceuticals sector with #1 Institutional Investor ranked team. Assessed future earnings potential of companies through comprehensive financial and therapeutic area analysis, establishing foundation for recommendations. Produced company reports including coverage initiations, earnings evaluations, and analysis of strategic initiatives in a time-sensitive environment, resulting in quickly delivering actionable opinions to investors.

Sellside equity research coverage of the US Specialty Pharmaceuticals sector with #1 Institutional Investor ranked team. Assessed future earnings potential of companies through comprehensive financial and therapeutic area analysis, establishing foundation for recommendations. Produced company reports including coverage initiations, earnings evaluations, and analysis of strategic initiatives in a time-sensitive environment, resulting in quickly delivering actionable opinions to investors.

Sellside equity research coverage of the US Specialty Pharmaceuticals sector with #1 Institutional Investor ranked team. Assessed future earnings potential of companies through comprehensive financial and therapeutic area analysis, establishing foundation for recommendations. Produced company reports including coverage initiations, earnings evaluations, and analysis of strategic initiatives in a time-sensitive environment, resulting in quickly delivering actionable opinions to investors.

Generated buyside stock and sector recommendations from US and Canadian equity markets based on research and screening approaches.

Exchange Program with The Wharton School